Do analysts recommend NIOX or MXCT?

NIOX Group presently has a consensus target price of GBX 86, indicating a potential upside of 41.56%. Given NIOX Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe NIOX Group is more favorable than MaxCyte. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NIOX Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 MaxCyte 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, NIOX or MXCT?

NIOX Group has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NIOX Group £48.70M 5.24 £995.88M £1.64 37.04 MaxCyte £32.29M 0.04 -£45.08M -£40.00 N/A

Is NIOX or MXCT more profitable?

NIOX Group has a net margin of 14.37% compared to MaxCyte's net margin of -120.39%. NIOX Group's return on equity of 10.14% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets NIOX Group 14.37% 10.14% 3.95% MaxCyte -120.39% -16.71% -11.07%

Do analysts rate IUG or NIOX?

NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 41.56%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts clearly believe NIOX Group is more favorable than Intelligent Ultrasound Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Ultrasound Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NIOX Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer NCYT or NIOX?

NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 41.56%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts clearly believe NIOX Group is more favorable than Novacyt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novacyt 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NIOX Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings and valuation, NCYT or NIOX?

NIOX Group has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novacyt £20.03M 1.50 -£36.80M -£43.00 N/A NIOX Group £48.70M 5.24 £995.88M £1.64 37.04

Is NCYT or NIOX more profitable?

NIOX Group has a net margin of 14.37% compared to Novacyt's net margin of -135.96%. NIOX Group's return on equity of 10.14% beat Novacyt's return on equity. Company Net Margins Return on Equity Return on Assets Novacyt -135.96% -121.30% -27.98% NIOX Group 14.37% 10.14% 3.95%

NIOX Group (NIOX) Competitors

GBX 60.75 +1.75 (+2.97%)

As of 10:56 AM Eastern

Compare

NIOX vs. MXCT, EKF, CREO, IUG, and NCYT

Should you buy NIOX Group stock or one of its competitors? MarketBeat compares NIOX Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NIOX Group include MaxCyte (MXCT), EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), and Novacyt (NCYT). These companies are all part of the "medical devices" industry.

How does NIOX Group compare to MaxCyte?

NIOX Group (LON:NIOX) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

17.4% of NIOX Group shares are held by institutional investors. Comparatively, 24.0% of MaxCyte shares are held by institutional investors. 4.9% of NIOX Group shares are held by insiders. Comparatively, 1.9% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, NIOX Group had 4 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for NIOX Group and 0 mentions for MaxCyte. NIOX Group's average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Overall Sentiment
NIOX Group	Neutral
MaxCyte	Neutral

NIOX Group has a net margin of 14.37% compared to MaxCyte's net margin of -120.39%. NIOX Group's return on equity of 10.14% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
MaxCyte	-120.39%	-16.71%	-11.07%

NIOX Group has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.24	£995.88M	£1.64	37.04
MaxCyte	£32.29M	0.04	-£45.08M	-£40.00	N/A

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

NIOX Group presently has a consensus target price of GBX 86, indicating a potential upside of 41.56%. Given NIOX Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe NIOX Group is more favorable than MaxCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
MaxCyte	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

NIOX Group beats MaxCyte on 13 of the 15 factors compared between the two stocks.

How does NIOX Group compare to EKF Diagnostics?

NIOX Group (LON:NIOX) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

NIOX Group has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.526, indicating that its share price is 47% less volatile than the broader market.

In the previous week, NIOX Group had 3 more articles in the media than EKF Diagnostics. MarketBeat recorded 4 mentions for NIOX Group and 1 mentions for EKF Diagnostics. NIOX Group's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company	Overall Sentiment
NIOX Group	Neutral
EKF Diagnostics	Neutral

NIOX Group has higher earnings, but lower revenue than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.24	£995.88M	£1.64	37.04
EKF Diagnostics	£51.56M	2.21	£4.68M	£0.47	56.38

NIOX Group presently has a consensus target price of GBX 86, suggesting a potential upside of 41.56%. EKF Diagnostics has a consensus target price of GBX 35, suggesting a potential upside of 32.08%. Given NIOX Group's higher probable upside, analysts plainly believe NIOX Group is more favorable than EKF Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NIOX Group has a net margin of 14.37% compared to EKF Diagnostics' net margin of 4.12%. NIOX Group's return on equity of 10.14% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
EKF Diagnostics	4.12%	3.01%	5.27%

17.4% of NIOX Group shares are held by institutional investors. Comparatively, 22.6% of EKF Diagnostics shares are held by institutional investors. 4.9% of NIOX Group shares are held by insiders. Comparatively, 39.7% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

NIOX Group beats EKF Diagnostics on 8 of the 13 factors compared between the two stocks.

How does NIOX Group compare to Creo Medical Group?

NIOX Group (LON:NIOX) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Creo Medical Group has a net margin of 88.33% compared to NIOX Group's net margin of 14.37%. NIOX Group's return on equity of 10.14% beat Creo Medical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.37%	10.14%	3.95%
Creo Medical Group	88.33%	9.56%	-20.09%

17.4% of NIOX Group shares are held by institutional investors. Comparatively, 45.2% of Creo Medical Group shares are held by institutional investors. 4.9% of NIOX Group shares are held by insiders. Comparatively, 4.1% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NIOX Group currently has a consensus target price of GBX 86, suggesting a potential upside of 41.56%. Creo Medical Group has a consensus target price of GBX 40, suggesting a potential upside of 194.12%. Given Creo Medical Group's higher probable upside, analysts clearly believe Creo Medical Group is more favorable than NIOX Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Creo Medical Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NIOX Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£48.70M	5.24	£995.88M	£1.64	37.04
Creo Medical Group	£6M	9.35	-£25.04M	-£1.00	N/A

In the previous week, NIOX Group had 4 more articles in the media than Creo Medical Group. MarketBeat recorded 4 mentions for NIOX Group and 0 mentions for Creo Medical Group. Creo Medical Group's average media sentiment score of 0.05 beat NIOX Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
NIOX Group	Neutral
Creo Medical Group	Neutral

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6238419, suggesting that its share price is 62% more volatile than the broader market.

Summary

NIOX Group beats Creo Medical Group on 10 of the 16 factors compared between the two stocks.

How does NIOX Group compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and NIOX Group (LON:NIOX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, NIOX Group had 4 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 4 mentions for NIOX Group and 0 mentions for Intelligent Ultrasound Group. Intelligent Ultrasound Group's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company	Overall Sentiment
Intelligent Ultrasound Group	Neutral
NIOX Group	Neutral

75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. Comparatively, 17.4% of NIOX Group shares are owned by institutional investors. 12.8% of Intelligent Ultrasound Group shares are owned by company insiders. Comparatively, 4.9% of NIOX Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Intelligent Ultrasound Group has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 41.56%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts clearly believe NIOX Group is more favorable than Intelligent Ultrasound Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Ultrasound Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NIOX Group has a net margin of 14.37% compared to Intelligent Ultrasound Group's net margin of -23.11%. NIOX Group's return on equity of 10.14% beat Intelligent Ultrasound Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Ultrasound Group	-23.11%	-23.58%	-13.51%
NIOX Group	14.37%	10.14%	3.95%

NIOX Group has higher revenue and earnings than Intelligent Ultrasound Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Ultrasound Group	£6.57M	0.00	-£2.27M	-£0.68	N/A
NIOX Group	£48.70M	5.24	£995.88M	£1.64	37.04

Summary

NIOX Group beats Intelligent Ultrasound Group on 12 of the 14 factors compared between the two stocks.

How does NIOX Group compare to Novacyt?

Novacyt (LON:NCYT) and NIOX Group (LON:NIOX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

NIOX Group has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novacyt	£20.03M	1.50	-£36.80M	-£43.00	N/A
NIOX Group	£48.70M	5.24	£995.88M	£1.64	37.04

NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 41.56%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts clearly believe NIOX Group is more favorable than Novacyt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novacyt	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, NIOX Group had 3 more articles in the media than Novacyt. MarketBeat recorded 4 mentions for NIOX Group and 1 mentions for Novacyt. NIOX Group's average media sentiment score of 0.00 beat Novacyt's score of -0.49 indicating that NIOX Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Novacyt	Neutral
NIOX Group	Neutral

10.7% of Novacyt shares are held by institutional investors. Comparatively, 17.4% of NIOX Group shares are held by institutional investors. 0.5% of Novacyt shares are held by company insiders. Comparatively, 4.9% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novacyt has a beta of 0.973, suggesting that its share price is 3% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

NIOX Group has a net margin of 14.37% compared to Novacyt's net margin of -135.96%. NIOX Group's return on equity of 10.14% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novacyt	-135.96%	-121.30%	-27.98%
NIOX Group	14.37%	10.14%	3.95%

Summary

NIOX Group beats Novacyt on 15 of the 16 factors compared between the two stocks.

Get NIOX Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NIOX vs. The Competition

Export

Metric	NIOX Group	Medical Devices Industry	Medical Sector	LON Exchange
Market Cap	£255.41M	£2.07B	£6.25B	£2.79B
Dividend Yield	2.72%	2.68%	2.69%	6.13%
P/E Ratio	37.04	14.22	21.07	364.76
Price / Sales	5.24	122.00	556.32	87,562.76
Price / Cash	11.21	15.99	42.31	27.85
Price / Book	3.37	4.40	9.78	7.67
Net Income	£995.88M	£144.75M	£3.56B	£5.88B
7 Day Performance	2.97%	1.46%	-0.18%	6.53%
1 Month Performance	-9.33%	0.08%	4.95%	9.76%
1 Year Performance	-14.91%	5.32%	28.44%	75.45%

NIOX Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NIOX NIOX Group	2.2425 of 5 stars	GBX 60.75 +3.0%	GBX 86 +41.6%	-13.5%	£255.41M	£48.70M	37.04	92
MXCT MaxCyte	N/A	GBX 1.17 +8.3%	N/A	-99.3%	£170.11M	£32.29M	N/A	80	High Trading Volume
EKF EKF Diagnostics	1.8648 of 5 stars	GBX 26.93 -1.0%	GBX 35 +30.0%	+3.5%	£115.93M	£51.56M	57.30	356	News Coverage
CREO Creo Medical Group	N/A	GBX 14.13 -2.6%	GBX 40 +183.2%	-8.9%	£58.26M	£6M	N/A	279
IUG Intelligent Ultrasound Group	N/A	N/A	N/A	N/A	£42.76M	£6.57M	N/A	65

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:NIOX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NIOX Group (NIOX) Competitors

NIOX vs. MXCT, EKF, CREO, IUG, and NCYT

How does NIOX Group compare to MaxCyte?

Summary

How does NIOX Group compare to EKF Diagnostics?

Summary

How does NIOX Group compare to Creo Medical Group?

Summary

How does NIOX Group compare to Intelligent Ultrasound Group?

Summary

How does NIOX Group compare to Novacyt?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIOX vs. The Competition

NIOX Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NIOX Group (NIOX) Competitors

NIOX vs. MXCT, EKF, CREO, IUG, and NCYT

How does NIOX Group compare to MaxCyte?

Do insiders & institutionals believe in NIOX or MXCT?

Does the media favor NIOX or MXCT?

Is NIOX or MXCT more profitable?

Which has preferable valuation and earnings, NIOX or MXCT?

Which has more volatility and risk, NIOX or MXCT?

Do analysts recommend NIOX or MXCT?

Summary

How does NIOX Group compare to EKF Diagnostics?

Which has more volatility and risk, NIOX or EKF?

Does the media favor NIOX or EKF?

Which has stronger valuation and earnings, NIOX or EKF?

Do analysts prefer NIOX or EKF?

Is NIOX or EKF more profitable?

Do institutionals and insiders have more ownership in NIOX or EKF?

Summary

How does NIOX Group compare to Creo Medical Group?

Is NIOX or CREO more profitable?

Do insiders & institutionals hold more shares of NIOX or CREO?

Do analysts rate NIOX or CREO?

Which has preferable valuation and earnings, NIOX or CREO?

Does the media refer more to NIOX or CREO?

Which has more risk & volatility, NIOX or CREO?

Summary

How does NIOX Group compare to Intelligent Ultrasound Group?

Does the media favor IUG or NIOX?

Do insiders and institutionals have more ownership in IUG or NIOX?

Which has more risk and volatility, IUG or NIOX?

Do analysts rate IUG or NIOX?

Is IUG or NIOX more profitable?

Which has preferable valuation and earnings, IUG or NIOX?

Summary

How does NIOX Group compare to Novacyt?

Which has better earnings and valuation, NCYT or NIOX?

Do analysts prefer NCYT or NIOX?

Does the media favor NCYT or NIOX?

Do insiders and institutionals hold more shares of NCYT or NIOX?

Which has more risk & volatility, NCYT or NIOX?

Is NCYT or NIOX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIOX vs. The Competition

NIOX Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools